Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Cancer

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Compensated Cirrhosis in a 40-Year-Old Woman With Progressive Familial Intrahepatic Cholestasis Type 3.

ACG case reports journal·2026

Same author

A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.

Hepatology international·2026

Same author

A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.

Hepatology (Baltimore, Md.)·2026

Same author

A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.

Annals of hepatology·2026

Same author

A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.

Journal of hepatology·2026

Same author

Circulating Tumor Cells as the Liquid Biopsy Foray into Noninvasive Colorectal Cancer Screening.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026

Search research articles

Related Experiment Video

Updated: Nov 28, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

New Names for Old Tumors.

Mary Wong¹, Kevin M Waters¹, Maha Guindi¹

¹Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.

American Journal of Clinical Pathology

|December 1, 2020

Summary

New clear cell subtypes of hepatocellular carcinoma (HCC), including steatohepatitic (SH-HCC), steatotic (S-HCC), and chromophobe (C-HCC), can classify most clear cell HCCs. These subtypes show distinct clinical-pathologic features, warranting further research for standardized definitions.

Keywords:

Hepatocellular carcinoma atty liver disease iver lear cell teatohepatitis teatosis

More Related Videos

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Published on: February 28, 2019

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Related Experiment Videos

Last Updated: Nov 28, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Published on: February 28, 2019

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Area of Science:

Hepatobiliary pathology
Oncology
Tumor classification

Background:

Clear cell hepatocellular carcinoma (HCC) has varied definitions.
New subtypes like chromophobe (C-HCC), steatohepatitic (SH-HCC), and steatotic (S-HCC) have been proposed.
The clinical-pathologic utility of these subtypes requires assessment.

Purpose of the Study:

To assess the utility and clinical-pathologic profile of proposed clear cell HCC subtypes.
To apply current histologic definitions to previously characterized clear cell HCCs.
To analyze histologic and clinical variables associated with these subtypes.

Main Methods:

Applied current histologic definitions, including three for SH-HCC, to 66 clear cell HCCs.
Classified tumors into SH-HCC, S-HCC, and C-HCC subtypes.
Analyzed correlations between subtypes and clinical-pathologic variables.

Main Results:

51 of 66 (77%) clear cell HCCs were classified into subtypes: 34 SH-HCC, 15 S-HCC, 2 C-HCC.
Different SH-HCC definitions impacted classification rates.
S-HCC and SH-HCC were associated with steatotic clear cells; S-HCC also showed early type and low grade features.
Unclassified tumors had flocculent cytoplasm but no distinct profile.

Conclusions:

Current definitions can reclassify most clear cell HCCs.
The proposed subtypes correlate with specific variables, indicating distinct profiles.
Further research is needed to standardize SH-HCC definitions.